Close Menu

NEW YORK (GenomeWeb) – Foundation Medicine and the Sarah Cannon Research Institute are collaborating to use genomic profiling as part of clinical trials, the organizations said today.

Under the partnership, researchers can use Foundation Medicine's FoundationOne assay for solid tumors, FoundationOne Heme for hematologic cancers, and FoundationACT for liquid biopsy analysis to identify patients eligible for Sarah Cannon's clinical studies.

Sarah Cannon will also integrate Foundation's decision support portal, called Interactive Cancer Explorer, across its network.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Jun
13
Sponsored by
Roche

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
17
Sponsored by
Illumina

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
26
Sponsored by
Lexogen

This webinar will outline a study that combined genome-wide and classical molecular approaches to demonstrate that translation strongly affects mRNA stability in a codon-dependent manner, ultimately influencing mRNA and protein levels in higher organisms.